Skip to content

INVO Fertility, Inc.: financial reference

Explore INVO Fertility, Inc. financial histories from SEC filings, with original units, reporting periods, filing dates and downloadable source data.

Limits of the selected measures

us-gaap:WeightedAverageNumberOfSharesOutstandingBasic: These 2014 INVO weighted-average shares are withheld because the main statement reports 112,672,160 while the per-share note reports 112,670,160 for the same annual period. The source disagreement is retained; neither number is substituted or treated as a rounding correction.

Inspect 1 withheld observation (period ends: 2014-12-31)
Withheld source values: WeightedAverageNumberOfSharesOutstandingBasic. These values are excluded from the selected history.
Period startPeriod endOriginal valueUnitSource filing
2014-01-012014-12-31112672160shares0001185185-17-000595

us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding: These 2014 INVO weighted-average shares are withheld because the main statement reports 112,672,160 while the per-share note reports 112,670,160 for the same annual period. The source disagreement is retained; neither number is substituted or treated as a rounding correction.

Inspect 1 withheld observation (period ends: 2014-12-31)
Withheld source values: WeightedAverageNumberOfDilutedSharesOutstanding. These values are excluded from the selected history.
Period startPeriod endOriginal valueUnitSource filing
2014-01-012014-12-31112672160shares0001185185-17-000595

Context from the filing

INVO Fertility's 2024 and 2025 total loss EPS uses losses attributable to common shareholders, including preferred dividends and deemed dividends, rather than the separate continuing-operations EPS. The filing displays full dollar amounts and shares and retrospectively reflects one-for-12, one-for-3 and one-for-8 splits effective March 18, July 21 and November 28, 2025, and a one-for-5 split effective March 27, 2026. Potential shares are excluded as anti-dilutive during losses. Earlier INVO Bioscience observations retain their historical filing basis; both disputed 2014 share counts remain withheld. Read the source filing.

For INVO Bioscience in 2011–2014, potential shares were excluded from diluted loss per share because their inclusion would have been anti-dilutive during losses. The reviewed figures are USD EPS for those four years and full weighted-average share counts for 2011–2013. Both 2014 share counts remain withheld: the main statement reports 112,672,160 while the per-share note reports 112,670,160. EPS is retained as reported, not recomputed from either disputed denominator. These are the historical filing’s share and period conventions. Read the source filing.

Reported financial histories

Choose a measure to inspect its definition, complete selected history and filing provenance. Each row shows the latest period available for that selected concept and original unit. Separate currencies and reporting intervals remain separate rows. Coverage dates can differ between concepts. A recent capture does not imply recent accounting coverage; these amounts are not prices.

Latest periods by selected concept and original unit
MeasurePeriod startPeriod endValueUnitFiled
Total assetsAt date2025-12-3120,220,124USD2026-06-02
Total liabilitiesAt date2025-12-3112,995,903USD2026-06-02
Stockholders equityAt date2025-12-317,224,221USD2026-06-02
Cash and cash equivalentsAt date2021-12-315,684,871USD2022-03-31
Net income or loss2025-01-012025-12-31-23,323,054USD2026-06-02
Operating cash flow2025-01-012025-12-31-7,014,485USD2026-06-02
Capital expenditure payments2025-01-012025-12-3143,412USD2026-06-02
Revenue2025-01-012025-12-316,841,250USD2026-06-02
Contract revenue excluding tax2024-01-012024-12-316,561,000USD2025-04-30
Financing cash flow2025-01-012025-12-3111,096,412USD2026-06-02
Investing cash flow2025-01-012025-12-31-2,745,481USD2026-06-02
Retained earnings or deficitAt date2025-12-31-91,369,403USD2026-06-02
Basic weighted-average shares2025-01-012025-12-31117,083shares2026-06-02
Diluted weighted-average shares2025-01-012025-12-31117,083shares2026-06-02
Basic earnings per share2025-01-012025-12-31-214.64USD/shares2026-06-02
Diluted earnings per share2025-01-012025-12-31-214.64USD/shares2026-06-02
Income tax expense or benefit2025-01-012025-12-31-150,371USD2026-06-02
Net property, plant and equipmentAt date2025-12-31386,165USD2026-06-02
Share-based compensation expense2025-01-012025-12-31162,920USD2026-06-02
Operating income or loss2025-01-012025-12-31-7,237,356USD2026-06-02
Current assetsAt date2025-12-312,761,503USD2026-06-02
Interest expense2024-01-012024-12-311,056,360USD2025-04-30
Current liabilitiesAt date2025-12-3110,331,629USD2026-06-02
Current accounts payableAt date2020-12-31328,927USD2021-03-30
Net finite-lived intangible assetsAt date2025-12-311,259,786USD2026-06-02
Net current accounts receivableAt date2025-12-31217,263USD2026-06-02
Operating expenses2024-01-012024-12-3114,657,496USD2025-04-30
Net inventoryAt date2025-12-31225,253USD2026-06-02
Gross profit2022-01-012022-12-31490,673USD2023-04-17
Cost of revenue2024-01-012024-12-313,717,245USD2025-04-30
Selling, general and administrative expense2025-01-012025-12-317,691,151USD2026-06-02
Research and development expense2024-01-012024-12-314,880USD2026-06-02

Inspect the source

Entity
INVO Fertility, Inc. / CIK 0001417926
Captured
2026-09-20T08:02:38.408Z
SEC response SHA-256
685ad9dc506bdfe829560566a030c772be69de24616cba6e2a255a48eadc071b

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001417926.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))